Deciphera Pharmaceuticals Quarterly Income Statements Chart
Quarterly
|
Annual
Deciphera Pharmaceuticals Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues: | |||||||||||||||||||||||||||
| product revenues | 42,550,000 | 46,712,000 | 41,820,000 | 37,320,000 | 33,222,000 | 32,880,000 | 32,318,000 | 31,497,000 | 28,809,000 | 23,697,000 | 21,682,000 | 22,048,000 | 19,962,000 | 19,472,000 | 15,164,000 | 4,825,000 | |||||||||||
| collaboration revenues | 2,449,000 | 1,582,000 | 1,493,000 | 984,000 | 223,000 | 3,465,000 | 3,656,000 | 997,000 | 414,000 | 502,000 | 1,538,000 | 1,525,000 | 5,194,000 | 14,000 | 285,000 | 2,265,000 | |||||||||||
| total revenues | 44,999,000 | 48,294,000 | 43,313,000 | 38,304,000 | 33,445,000 | 36,345,000 | 35,974,000 | 32,494,000 | 29,223,000 | 24,199,000 | 23,220,000 | 23,573,000 | 25,156,000 | 19,486,000 | 15,449,000 | 7,090,000 | |||||||||||
| cost and operating expenses: | |||||||||||||||||||||||||||
| cost of sales | 2,088,000 | 1,785,000 | 1,286,000 | 173,000 | 488,000 | 3,245,000 | 3,344,000 | 1,799,000 | 382,000 | 518,000 | 917,000 | 1,275,000 | 222,000 | 127,000 | 90,000 | 8,000 | |||||||||||
| gross profit | |||||||||||||||||||||||||||
| yoy | |||||||||||||||||||||||||||
| qoq | |||||||||||||||||||||||||||
| gross margin % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |||||||||||||||||
| research and development | 57,834,000 | 58,599,000 | 62,463,000 | 58,296,000 | 54,765,000 | 48,066,000 | 47,485,000 | 44,858,000 | 47,412,000 | 74,931,000 | 66,444,000 | 59,984,000 | 55,681,000 | 52,288,000 | 49,213,000 | 46,081,000 | 51,388,000 | 46,636,000 | 40,374,000 | 34,811,000 | 35,789,000 | 27,356,000 | 20,630,000 | 17,976,000 | 16,925,000 | 15,658,000 | 9,751,000 |
| selling, general, and administrative | 33,924,000 | 39,148,000 | 33,252,000 | 32,610,000 | 31,449,000 | 32,195,000 | 30,026,000 | 29,625,000 | 28,321,000 | 37,151,000 | 35,527,000 | 32,828,000 | 30,747,000 | 30,070,000 | 30,143,000 | 29,933,000 | 23,936,000 | ||||||||||
| total cost and operating expenses | 93,846,000 | 99,532,000 | 97,001,000 | 91,079,000 | 86,702,000 | 83,506,000 | 80,855,000 | 76,282,000 | 76,115,000 | 112,600,000 | 102,888,000 | 94,087,000 | 86,650,000 | 82,485,000 | 79,446,000 | 76,022,000 | |||||||||||
| income from operations | -48,847,000 | -51,238,000 | -53,688,000 | -52,775,000 | -53,257,000 | -47,161,000 | -44,881,000 | -43,788,000 | -46,892,000 | -88,401,000 | -79,668,000 | -70,514,000 | -61,494,000 | -62,999,000 | -63,997,000 | -68,932,000 | -75,262,000 | -70,373,000 | -58,353,000 | -22,975,000 | -49,025,000 | -33,830,000 | -25,889,000 | -22,429,000 | -21,951,000 | -20,338,000 | -12,181,000 |
| yoy | -8.28% | 8.64% | 19.62% | 20.52% | 13.57% | -46.65% | -43.66% | -37.90% | -23.75% | 40.32% | 24.49% | 2.30% | -18.29% | -10.48% | 9.67% | 200.03% | 53.52% | 108.02% | 125.40% | 2.43% | 123.34% | 66.34% | 112.54% | ||||
| qoq | -4.67% | -4.56% | 1.73% | -0.91% | 12.93% | 5.08% | 2.50% | -6.62% | -46.96% | 10.96% | 12.98% | 14.67% | -2.39% | -1.56% | -7.16% | -8.41% | 6.95% | 20.60% | 153.98% | -53.14% | 44.92% | 30.67% | 15.43% | 2.18% | 7.93% | 66.96% | |
| operating margin % | -634.29% | -324.56% | -174.53% | -370.39% | -522.55% | -492.28% | -503.68% | -436.75% | -434.57% | -501.28% | |||||||||||||||||
| other income: | |||||||||||||||||||||||||||
| interest and other income | 3,764,000 | 4,479,000 | 4,107,000 | 4,213,000 | 3,648,000 | 1,948,000 | 1,838,000 | 727,000 | 6,000 | -170,000 | 81,000 | 196,000 | 259,000 | 296,000 | 1,691,000 | 2,455,000 | 3,169,000 | 2,174,000 | 1,540,000 | 1,654,000 | 1,551,000 | 1,475,000 | 760,000 | 543,000 | |||
| total other income | 3,764,000 | 4,479,000 | 4,107,000 | 4,213,000 | 3,648,000 | 1,948,000 | 1,838,000 | 727,000 | 6,000 | -170,000 | 81,000 | 196,000 | 259,000 | 296,000 | 1,691,000 | 2,455,000 | 3,157,000 | 2,157,000 | 1,515,000 | 1,641,000 | 1,531,000 | 1,454,000 | 739,000 | 521,000 | 426,000 | 143,000 | |
| net income | -45,083,000 | -47,190,000 | -49,581,000 | -48,562,000 | -49,609,000 | -45,935,000 | -43,043,000 | -43,061,000 | -46,892,000 | -88,395,000 | -79,838,000 | -70,433,000 | -61,298,000 | -62,740,000 | -63,701,000 | -67,241,000 | -72,807,000 | -67,216,000 | -56,196,000 | -21,460,000 | -47,384,000 | ||||||
| yoy | -9.12% | 2.73% | 15.19% | 12.77% | 5.79% | -48.03% | -46.09% | -38.86% | -23.50% | 40.89% | 25.33% | 4.75% | -15.81% | -6.66% | 13.36% | 213.33% | 53.65% | ||||||||||
| qoq | -4.46% | -4.82% | 2.10% | -2.11% | 8.00% | 6.72% | -0.04% | -8.17% | -46.95% | 10.72% | 13.35% | 14.90% | -2.30% | -1.51% | -5.26% | -7.64% | 8.32% | 19.61% | 161.86% | -54.71% | |||||||
| net income margin % | -605.84% | -312.56% | -163.02% | -357.99% | 0% | 0% | 0% | 0% | 0% | 0% | |||||||||||||||||
| net income per share | -0.52 | -0.54 | -0.58 | -0.57 | -0.6 | -0.55 | -0.55 | -0.6 | -0.8 | -1.51 | -1.37 | -1.21 | -1.06 | -1.1 | -1.13 | -1.2 | -1.36 | -1.36 | -1.28 | -0.56 | -1.25 | -0.87 | -0.65 | -0.65 | -0.66 | 11.77 | -5.85 |
| weighted-average common shares outstanding—basic and diluted | 87,388,106 | 85,059,962 | 85,788,613 | 85,020,344 | 82,676,624 | 75,500,148 | 78,206,647 | 72,133,428 | 58,616,458 | 58,084,325 | 58,107,611 | 57,987,095 | 57,747,168 | 55,780,982 | 56,390,748 | 55,920,122 | 53,567,434 | 42,869,058 | 43,803,508 | 38,200,288 | 38,057,018 | 35,390,480 | 37,654,324 | 33,567,314 | 32,594,074 | 16,792,179 | |
| comprehensive loss: | |||||||||||||||||||||||||||
| other comprehensive income: | |||||||||||||||||||||||||||
| unrealized gains on marketable securities | -206 | 978 | 250 | -540 | -246 | -9 | 30 | -28 | 47 | -771 | 652 | 50 | -114 | 154 | 21 | ||||||||||||
| currency translation adjustment | -273 | 495 | -179 | 108 | 93 | 432 | -352 | -48 | -74 | 132 | 148 | 36 | 2 | ||||||||||||||
| total other comprehensive income | -479 | 1,473 | 71 | -786 | 802 | 1,059 | -774 | -705 | -614 | -114 | 139 | -17 | 32 | -28 | 47 | -771 | 652 | 50 | -114 | 154 | 21 | ||||||
| total comprehensive loss | -45,562 | -45,717 | -49,510 | -49,348 | -48,807 | -44,876 | -43,817 | -43,766 | -47,506 | -88,509 | -79,699 | -70,450 | -61,266 | -62,768 | -63,654 | -68,012 | -72,155 | -67,166 | -56,310 | -21,306 | -47,363 | ||||||
| unrealized losses on marketable securities | -894 | 709 | 627 | -422 | -657 | -53 | |||||||||||||||||||||
| interest expense | -12,000 | -17,000 | -25,000 | -13,000 | -20,000 | -21,000 | -21,000 | -22,000 | -23,000 | -23,000 | |||||||||||||||||
| revenues | 62,000 | ||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||
| total operating expenses | 75,324,000 | 70,373,000 | 58,353,000 | 47,975,000 | 49,025,000 | 33,830,000 | 25,889,000 | 22,429,000 | 21,951,000 | 20,338,000 | 12,181,000 | ||||||||||||||||
| general and administrative | 11,094,750 | 17,979,000 | 13,164,000 | 13,236,000 | 6,474,000 | 5,259,000 | 4,453,000 | 5,026,000 | 4,680,000 | 2,430,000 | |||||||||||||||||
| revenue | 25,000,000 | ||||||||||||||||||||||||||
| yoy | |||||||||||||||||||||||||||
| qoq | |||||||||||||||||||||||||||
| net income and comprehensive loss | -32,299,000 | -24,435,000 | -21,690,000 | -21,430,000 | -19,912,000 | -12,038,000 | |||||||||||||||||||||
| other income | 74,250 | 166,000 | |||||||||||||||||||||||||
| net income attributable to series a convertible preferred shareholders—basic and diluted | -7,593,000 | -12,038,000 | |||||||||||||||||||||||||
| weighted-average series a convertible preferred shares outstanding—basic and diluted | 2,057,750 |
We provide you with 20 years income statements for Deciphera Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Deciphera Pharmaceuticals stock. Explore the full financial landscape of Deciphera Pharmaceuticals stock with our expertly curated income statements.
The information provided in this report about Deciphera Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.